MaxCyte, Inc. (MXCT) News
Filter MXCT News Items
MXCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MXCT News Highlights
- For MXCT, its 30 day story count is now at 6.
- Over the past 21 days, the trend for MXCT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CELL and MD are the most mentioned tickers in articles about MXCT.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
MaxCyte Appoints Douglas Swirsky as Chief Financial OfficerROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company’s Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over |
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call TranscriptMaxCyte, Inc. (NASDAQ:MXCT) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Good day and thank you for standing by and welcome to MaxCyte’s Fourth Quarter Earnings Conference Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Sean Menarguez of Investor […] |
MaxCyte Full Year 2022 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2021)MaxCyte ( LON:MXCT ) Full Year 2022 Results Key Financial Results Revenue: US$44.3m (up 31% from FY 2021). Net loss... |
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related RevenueROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced its fourth quarter and full ye |
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling TechnologyMaxCyte’s Scientific Advisory Board will provide guidance to shape the technical direction of the company’s innovation initiatives focused on the discovery, development and manufacturing of next-generation, cell-based medicinesROCKVILLE, Md., March 08, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based thera |
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue GuidanceMaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced preliminary revenue results for the fourth quarter and full year 2022 and provided initial 2023 revenue guidance. |
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards. |
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor ConferencesROCKVILLE, Md., Feb. 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative cell-based research, today announced that it will release financial results for the fourth quarter and full year 2022 after the U.S. market close on Wednesday, March 15th, 2023. Company management wil |
A fantastic week for MaxCyte, Inc.'s (LON:MXCT) 70% institutional owners, one-year returns continue to impressEvery investor in MaxCyte, Inc. ( LON:MXCT ) should be aware of the most powerful shareholder groups. The group holding... |
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy ProgramsMaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapiesROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic plat |